Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
arcticnovartis

  • V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1
  • 85% of patients on Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT1
/by

New Novartis ESC data highlights strength of cardiovascular portfolio

New Novartis ESC data highlights strength of cardiovascular portfolio
arcticnovartis

PRESS RELEASE

/by

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
arcticnovartis

/by

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by